News Summary: Amgen 4Q profit drops, costs rise

Published



PROFIT SLUMP: Biotech giant Amgen Inc.’s fourth-quarter net income dropped 16 percent to $788 million, or $1.01 per share, due to higher spending on production, marketing, research and other items.

SALES SURGE: Revenue rose 11 percent to $4.42 billion, as sales of immune disorder treatment Enbrel and four other drugs climbed by double digits. But part of the revenue jump was due to price increases.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.